FTC Clears $338M Baxter-Prism Pharmaceuticals Deal
By Pete Brush · May 6, 2011, 5:38 PM EDT
The Federal Trade Commission on Friday granted an early termination of its antitrust review of Baxter International Inc.'s purchase of Prism Pharmaceuticals Inc. in a deal worth up to $338 million...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login